Jazz Pharmaceuticals (JAZZ)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$246.81-0.31%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Research Workspace
Put JAZZ beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Revenue growth of at least 6% per year: rev +16% vs 6%.
View ThesisRevenue growth is accelerating — up about 13% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 22%.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskJAZZ's growth depends on the successful commercialization of Ziihera, which has shown positive trial results. Revenue grew 16% year over year, and the latest quarter beat expectations. It trades at 9.9× P/E versus a peer median of 16×, indicating that the price reflects less growth than anticipated. A specific risk is the potential for a credibility hit if guidance is cut after recent increases. Peer multiples imply a price about 16% above where it trades. Our read remains intact.
Trailing returns as of 2026-09-04. JAZZ is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 21 analysts currently covering JAZZ (as of Sep 2026).
Based on 13 Wall Street analysts offering 12-month price targets for JAZZ in the last 4 months.
Continue this research
Compare JAZZ with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| JAZZ Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Compare the value case
Put JAZZ next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance pipeline and regulatory activities
Ziihera's success enhances pipeline and regulatory activities.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $246.81
The last 12 months of price, then the range of analyst 12-month targets from today’s $246.81.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Advance pipeline and regulatory activities
Positive trial results support pipeline advancement.
Advances: Advance pipeline and regulatory activities
Approval enhances pipeline and regulatory activities significantly.
Advances: Increase revenue growth
Stock price target increase indicates confidence in revenue growth.
Advances: Advance pipeline and regulatory activities
Stock price target increase indicates positive label change expectations.
Advances: Advance pipeline and regulatory activities
FDA approval supports pipeline advancement and revenue growth.
Advances: Increase revenue growth
Commercial launch of Ziihera boosts revenue growth potential.
Raised guidance indicates confidence in future revenue growth.